Bill would expand 340B discounts for orphan drugs
Reps. Peter Welch (D-VT) and Gregg Harper (R-MS) yesterday introduced the Closing Loopholes for Orphan Drugs Act (H.R. 2889, legislation that would limit the “orphan drug” exclusion for 340B Drug Pricing Program rural and cancer hospitals. Specifically, the legislation would allow 340B critical access hospitals, sole community providers, rural referral centers and free-standing cancer hospitals to purchase orphan drugs at discounted rates through the 340B program as long as the orphan drug is used to treat illnesses or conditions other than the rare illnesses or conditions for which the orphan drug designation was originally given.
Related News Articles
Headline
The Department of Health and Human Services Feb. 13 issued a request for information on a new 340B rebate model program. The RFI said HHS’ Health Resources and…
Headline
The Senate Special Committee on Aging held a hearing Feb. 11 on issues impacting physician burnout. The AHA provided a statement for the hearing and urged…
Headline
The House Energy and Commerce Subcommittee on Health Feb. 11 hosted a hearing titled “Lowering Health Care Costs for All Americans: An Examination of the…
Headline
The 5th U.S. Circuit Court of Appeals Feb. 9 affirmed a district court ruling upholding Louisiana’s 340B contract pharmacy law. The state law prohibits…
Perspective
More than 34.1 million Americans were enrolled in a Medicare Advantage plan in 2025, accounting for 54% of all Medicare beneficiaries. We have seen enrollment…
Headline
The Department of Health and Human Services Feb. 5 in a court filing said it would scrap its current 340B Rebate Model Pilot Program and potentially restart…